Deutsche Bank AG Increases Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Deutsche Bank AG boosted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 39.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 316,205 shares of the biotechnology company's stock after buying an additional 89,851 shares during the quarter. Deutsche Bank AG owned approximately 0.41% of Axon Enterprise worth $187,927,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AXON. CoreCap Advisors LLC grew its position in shares of Axon Enterprise by 15.7% in the fourth quarter. CoreCap Advisors LLC now owns 3,223 shares of the biotechnology company's stock valued at $1,915,000 after purchasing an additional 437 shares during the period. Cetera Investment Advisers boosted its position in Axon Enterprise by 1.0% during the fourth quarter. Cetera Investment Advisers now owns 23,009 shares of the biotechnology company's stock worth $13,675,000 after acquiring an additional 236 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at about $3,506,000. Capstone Investment Advisors LLC raised its holdings in Axon Enterprise by 4.7% in the 4th quarter. Capstone Investment Advisors LLC now owns 1,505 shares of the biotechnology company's stock valued at $894,000 after acquiring an additional 67 shares during the last quarter. Finally, Captrust Financial Advisors lifted its stake in Axon Enterprise by 19.5% in the 4th quarter. Captrust Financial Advisors now owns 14,821 shares of the biotechnology company's stock worth $8,809,000 after purchasing an additional 2,415 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Analyst Ratings Changes

AXON has been the topic of a number of research reports. JMP Securities reissued an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Barclays raised their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Needham & Company LLC raised their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $652.73.

Insiders Place Their Bets

In other Axon Enterprise news, Director Julie A. Cullivan sold 657 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $700.00, for a total transaction of $459,900.00. Following the sale, the director now directly owns 1,735 shares in the company, valued at $1,214,500. This represents a 27.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 9,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $683.31, for a total transaction of $6,149,790.00. Following the sale, the president now owns 308,714 shares in the company, valued at approximately $210,947,363.34. This trade represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,964 shares of company stock worth $12,189,275 in the last ninety days. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Trading Up 0.5%

Shares of AXON stock traded up $3.76 during trading hours on Wednesday, hitting $728.53. The company had a trading volume of 566,004 shares, compared to its average volume of 764,892. The company's fifty day moving average is $572.18 and its 200 day moving average is $588.52. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $732.17. The stock has a market capitalization of $56.72 billion, a PE ratio of 188.25, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the business posted $1.15 EPS. The business's revenue for the quarter was up 31.3% compared to the same quarter last year. Research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.